T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses
Journal article
Ogbe A. et al, (2021), Nature Communications, 12
Therapeutic vaccination for treatment of chronic hepatitis B.
Journal article
Cargill T. and Barnes E., (2021), Clinical and experimental immunology, 205, 106 - 118
Hepatitis B virus (HBV) viral load, liver and renal function in adults treated with tenofovir disoproxil fumarate (TDF) vs. untreated: a retrospective longitudinal UK cohort study.
Journal article
Wang T. et al, (2021), BMC infectious diseases, 21
Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum.
Journal article
Liu C. et al, (2021), Cell
High cure rates for HCV genotype 6 in advanced liver fibrosis with 12 weeks sofosbuvir and daclatasvir: The Vietnam SEARCH Study
Journal article
Flower B. et al, (2021), Open Forum Infectious Diseases
Real world SOF/VEL/VOX retreatment outcomes and viral resistance analysis for HCV patients with prior failure to DAA therapy
Journal article
Smith DA. et al, (2021), Journal of Viral Hepatitis
Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
Journal article
Barrett JR. et al, (2021), Nature Medicine, 27, 1113 - 1113
Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
Journal article
Ewer KJ. et al, (2021), Nature Medicine, 27, 1116 - 1116
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial
Journal article
Frater J. et al, (2021), The Lancet HIV
A blood atlas of COVID-19 defines hallmarks of disease severity and specificity
Journal article
Ahern DJ. et al, (2021)
Longitudinal analysis of the utility of liver biochemistry in hospitalised COVID‐19 patients as prognostic markers
Journal article
Wang T. et al, (2021), Hepatology Communications
Global prevalence and phylogeny of hepatitis B virus (HBV) drug and vaccine resistance mutations.
Journal article
Mokaya J. et al, (2021), J Viral Hepat
Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera
Journal article
Zhou D. et al, (2021), Cell, 184, 2348 - 2361.e6
Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera
Journal article
Supasa P. et al, (2021), Cell, 184, 2201 - 2211.e7
A haemagglutination test for rapid detection of antibodies to SARS-CoV-2.
Journal article
Townsend A. et al, (2021), Nature communications, 12
COVID-19 and liver disease: mechanistic and clinical perspectives.
Journal article
Marjot T. et al, (2021), Nature reviews. Gastroenterology & hepatology
Antibody evasion by the P.1 strain of SARS-CoV-2
Journal article
Dejnirattisai W. et al, (2021), Cell
Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study.
Journal article
Marjot T. et al, (2021), Journal of hepatology, 74, 567 - 577
Risk factors for the development of hepatocellular carcinoma (HCC) in chronic hepatitis B virus (HBV) infection: a systematic review and meta‐analysis
Journal article
Campbell C. et al, (2021), Journal of Viral Hepatitis, 28, 493 - 507
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
Journal article
Voysey M. et al, (2021), The Lancet, 397, 881 - 891